НовостиBenzingaCerenome Completes Enrollment In Phase 2 ReSPECT-GBM Trial Of REYOBIQ In Recurrent Glioblastoma; Topline Data Expected Mid-2027 Cerenome Completes Enrollment In Phase 2 ReSPECT-GBM Trial Of REYOBIQ In Recurrent Glioblastoma; Topline Data Expected Mid-2027 Benzinga 2026.10.29 12:24 (GMT+0) Открыть на Benzinga Другие новости